Morfina Cloridrato S.A.L.F (Morphine Hydrochloride Trihydrate)

Morphine acts as an agonist at mu‑opioid receptors in the central nervous system. By activating these receptors, it inhibits the release of excitatory neurotransmitters, reduces neuronal firing, and diminishes the perception of pain, producing both analgesic and sedative effects.

The dose of morphine is individualized. A qualified prescriber determines the appropriate amount, route, frequency and duration based on the patient’s pain severity, prior opioid exposure, organ function and other clinical factors.

Safety data for morphine in pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, the drug is generally avoided unless the benefit outweighs potential risks. Clinicians should assess each case carefully.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Morphine has a slower onset and longer duration of action compared with fentanyl, which is highly lipophilic and provides rapid, potent analgesia. Morphine is often preferred for sustained pain control, while fentanyl is chosen for breakthrough pain or situations requiring rapid titration. Both require careful monitoring for respiratory depression.

Store the injectable solution at ambient temperature, below 25 °C, in its original packaging. Protect it from direct sunlight, moisture and extreme temperatures. Do not freeze. Follow standard aseptic techniques when preparing doses for administration.

The product is supplied as a sterile injectable solution and can be given epidurally, intramuscularly or intravenously by a qualified healthcare professional. The specific route, infusion rate or bolus volume is determined by the prescriber based on the clinical situation.

The most critical risks include respiratory depression, profound sedation, hypotension, severe constipation leading to bowel obstruction, development of physical dependence, tolerance and potential for abuse. Prompt recognition and intervention are essential to prevent life‑threatening complications.

Morphine is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, in those with severe respiratory insufficiency, acute or severe asthma, and in individuals who have taken monoamine‑oxidase inhibitors within the past 14 days. Caution is also advised in patients with uncontrolled head injury or increased intracranial pressure.